Form 4: Kiniksa COO Sells Shares After Option Exercise

Kiniksa Pharmaceuticals' Chief Operating Officer, Eben Tessari, exercised stock options and subsequently sold a portion of his Class A Ordinary Shares under a pre-arranged 10b5-1 plan.

Summary

• Eben Tessari, Chief Operating Officer of Kiniksa Pharmaceuticals International, plc, engaged in transactions involving Class A Ordinary Shares on December 15, 2025.
• Tessari exercised options to acquire 6,000 Class A Ordinary Shares at an exercise price of $8.83 per share.
• Immediately following the option exercise, Tessari sold 12,048 Class A Ordinary Shares at a weighted average price of $41.56 per share.
• The sale price ranged from $41.235 to $41.78 per share.
• All transactions were conducted pursuant to a Rule 10b5-1 trading plan established on April 29, 2024.
• After these transactions, Tessari's direct beneficial ownership of Class A Ordinary Shares stands at 16,666.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale can sometimes be viewed negatively, the fact that it was executed under a pre-planned 10b5-1 program mitigates concerns about immediate sentiment or future outlook. The exercise of options also indicates the monetization of vested equity.

Positives

• The option exercise indicates the executive is monetizing vested equity, which can be a sign of value realization.
• The transactions were executed under a pre-arranged 10b5-1 plan, suggesting a systematic approach to managing personal holdings rather than a reaction to immediate company news.

Negatives

• The sale of 12,048 shares by a Chief Operating Officer could be interpreted by some investors as a reduction in direct exposure to the company's equity, potentially signaling a lack of confidence, although mitigated by the 10b5-1 plan.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may interpret the insider sale as a signal, though the 10b5-1 plan suggests it's a routine personal financial management event rather than a reflection of company-specific concerns.

Key Dates

Keywords

Kiniksa Pharmaceuticals, KNSA, Eben Tessari, Insider Trading, Form 4, Stock Option Exercise, Share Sale, 10b5-1 Plan, Chief Operating Officer, Biotechnology